Renaissance Technologies LLC acquired a new position in Kadmon Holdings Inc (NYSE:KDMN) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 257,200 shares of the company’s stock, valued at approximately $1,026,000.
A number of other hedge funds also recently bought and sold shares of the stock. Vivo Capital LLC lifted its holdings in Kadmon by 213.6% in the second quarter. Vivo Capital LLC now owns 10,454,545 shares of the company’s stock worth $68,919,000 after purchasing an additional 7,121,212 shares during the period. BlackRock Inc. lifted its holdings in Kadmon by 209.3% in the second quarter. BlackRock Inc. now owns 4,763,436 shares of the company’s stock worth $19,005,000 after purchasing an additional 3,223,211 shares during the period. Millennium Management LLC lifted its holdings in Kadmon by 490.1% in the first quarter. Millennium Management LLC now owns 1,847,444 shares of the company’s stock worth $7,852,000 after purchasing an additional 1,534,371 shares during the period. VHCP Management II LLC acquired a new stake in Kadmon in the second quarter worth about $5,632,000. Finally, Asymmetry Capital Management L.P. lifted its holdings in Kadmon by 81.5% in the second quarter. Asymmetry Capital Management L.P. now owns 361,517 shares of the company’s stock worth $1,442,000 after purchasing an additional 162,370 shares during the period. 69.66% of the stock is owned by institutional investors and hedge funds.
Shares of Kadmon stock opened at $2.55 on Friday. Kadmon Holdings Inc has a 52 week low of $1.88 and a 52 week high of $5.86. The stock has a market capitalization of $269.18 million, a price-to-earnings ratio of -1.85 and a beta of 3.63.
Kadmon (NYSE:KDMN) last issued its quarterly earnings results on Thursday, August 9th. The company reported $0.24 EPS for the quarter, topping the consensus estimate of ($0.26) by $0.50. The business had revenue of $0.36 million during the quarter, compared to the consensus estimate of $0.90 million. On average, equities analysts anticipate that Kadmon Holdings Inc will post -0.94 EPS for the current year.
Several equities research analysts recently weighed in on KDMN shares. HC Wainwright set a $25.00 price objective on shares of Kadmon and gave the stock a “buy” rating in a report on Monday, August 13th. WBB Securities upgraded shares of Kadmon from a “sell” rating to a “hold” rating and set a $2.90 price target on the stock in a research report on Wednesday, October 17th. Finally, Zacks Investment Research cut shares of Kadmon from a “buy” rating to a “hold” rating in a research report on Thursday, October 11th. Three analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $11.43.
Kadmon Company Profile
Kadmon Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. The company markets and distributes a portfolio of branded generic ribavirin products for chronic hepatitis C virus infection; and distributes products in various therapeutic areas, including tetrabenazine for the treatment of chorea associated with Huntington's disease.
See Also: Trading Strategy Methods for Individual Investors
Want to see what other hedge funds are holding KDMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kadmon Holdings Inc (NYSE:KDMN).
Receive News & Ratings for Kadmon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon and related companies with MarketBeat.com's FREE daily email newsletter.